CAMBRIDGE, Mass, Feb 1 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Robert Hofmeister, Ph.D., as Chief Scientific Officer (CSO). An expert in immuno-oncology, gene and cell therapy, Dr. Hofmeister brings more than 25 years of scientific leadership experience and a track record of drug discovery and early development. “As […]
CAMBRIDGE, Mass, Jan 5, 2024 – Prime Medicine, Inc. (Nasdaq: PRME) (“Prime Medicine”) and Myeloid Therapeutics, Inc. (“Myeloid”), today announced resolution of all of their outstanding disputes, signaling an end to the pending arbitrations and a positive outcome for both parties. “I am happy we have reached an amicable settlement with Myeloid. We believe resolving […]
CAMBRIDGE, Mass, December 6, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has appointed Matthew Maurer, M.D. as Chief Medical Officer. Dr. Maurer is an experienced physician-scientist with over fifteen years of clinical oncology experience as a drug developer and a principal investigator advancing multiple cancer programs through the early and late […]
MT-302 arms myeloid cells with an mRNA-encoded CAR to kill tumor cells expressing TROP2, and trigger an adaptive immune response to metastatic epithelial tumors CAMBRIDGE, Mass, September 12, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic […]
Financing accelerates MT-302, the Company’s first clinical candidate for in vivo cell programming, into a Phase 1/2 clinical trial for TROP2+ solid tumors CAMBRIDGE, Mass., May 18, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, announced today the completion of a $73 million financing led by Hatteras Investment Partners, with participation from […]
Myeloid Therapeutics Presents Late-Breaking Data on Multiple Platforms at the American Association for Cancer Research (AACR) 2023 Annual Meeting CAMBRIDGE, Mass, April 17, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced its presentation of two posters at the American Association for Cancer Research (AACR) Annual Meeting, being held in Orlando, […]
Myeloid Therapeutics and New South Wales (NSW) Government in Australia Announce Collaboration to Design, Build, and Launch State-of-the-Art GMP Manufacturing Facility Dedicated to RNA Immunotherapies – NSW will invest AU $96 million to support the facility design, construction and roll-out – – Myeloid will operate the facility and bring its RNA know-how and leadership to […]
CAMBRIDGE, Mass, January 26, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that management will present at the Guggenheim Healthcare Talks 2023 Oncology Day, being held February 8-9, 2023, in New York, NY. Daniel Getts, Ph.D., CEO of Myeloid, will present a company overview on Wednesday, February 8, 2023, at […]
CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]
CAMBRIDGE, Mass, Nov. 10, 2022 /PRNewswire/ — Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that the Company will participate at the Jefferies London Healthcare Conference taking place from November 15-17, 2022 in London. Company management will meet one-on-one with investors during the conference. About Myeloid Therapeutics Myeloid Therapeutics is a clinical […]